Actively Recruiting
Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
Led by Dharmais National Cancer Center Hospital · Updated on 2025-11-18
136
Participants Needed
1
Research Sites
209 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.
CONDITIONS
Official Title
Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Breast cancer patients aged 218 years with an ECOG score > 1
- Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema
- Those who have never undergone lymphedema physiotherapy
You will not qualify if you...
- Patients with dermal backflow before axillary lymph node dissection (ALND)
- Patients unable to undergo a 24-month follow-up at Dharmais Cancer Hospital
- Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dharmais National Cancer Center
Jakarta, Jakarta Special Capital Region, Indonesia, 11420
Actively Recruiting
Research Team
A
Adhitya B Perdana, MEpi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here